Introduction {#s1}
============

Despite the substantial progress made in preventing foodborne diseases, new pathogens have emerged, some of which have spread worldwide decade after decade (Tauxe, [@B26]). These pathogens include strains of multi-drug resistant (MDR) *Salmonella* (Arlet et al., [@B3]; Walsh and Fanning, [@B29]). Their treatment in both animals and humans has become more difficult and the number of reports of foodborne infections and outbreaks of MDR *Salmonella* has increased (Angulo et al., [@B2]; Mølbak, [@B23]). The global spread of an MDR *Salmonella enterica* serotype Typhimurium phage type DT104 in animals and humans since the 1990s (Threlfall, [@B27]; Mather et al., [@B22]) is a good example. While the spread of DT104 may have been facilitated by the use of antimicrobials, the national and international trade of infected animals is thought to have played a major role in its spread across borders (Ribot et al., [@B25]; Weill et al., [@B31]).

More recently, an emerging *S.* Kentucky strain has been described (Weill et al., [@B32]; Le Hello et al., [@B18]) and belonged to the ST198-X1 subtype. It has accumulated various chromosomal resistance determinants since the mid-1990s with the integration of the *Salmonella* genomic island 1 (SGI1), a 43-kilobase genomic island initially described in DT104 (Boyd et al., [@B10]), encoding resistance to multiple antimicrobials including amoxicillin, gentamicin, and sulfonamides (Doublet et al., [@B12]), followed by cumulative mutations in the *gyrA* and *parC* genes, leading to resistance to nalidixic acid and then to ciprofloxacin in 2002 (*S.* Kentucky CIP-R). This population was mostly detected in Egypt before 2005, but has now rapidly spread throughout Africa and the Middle East (Le Hello et al., [@B18]). Another matter of concern is the expanding livestock reservoir of this *S.* Kentucky CIP-R strain. It was initially identified in autochthonous poultry but was then found in various animals and foods (contaminated spices in France and the United States of America (US), turkey flocks in Germany and Poland, wild animals, etc) (Le Hello et al., [@B18]; Beutlich et al., [@B7]; Münch et al., [@B24]; Wasyl and Hoszowski, [@B30]). Several isolates give rise to considerable concern, as they have become producers of various carbapenemases and/or cephamycinase and/or extended spectrum β-lactamases (ESBL) (Le Hello et al., [@B17]).

Since these studies, several reports have mentioned *S.* Kentucky CIP-R isolates that have been identified from different sources (animals, food, the environment and humans) and geographic locations, in particular in several new countries in the Indian sub-continent and Southeast Asia. The purpose of this study was to examine whether the *S.* Kentucky strains isolated around the world from different ecosystems belong to this expanding ST198-X1-SGI1 strain.

Materials and methods {#s2}
=====================

Collection of strains
---------------------

Following the publication of the first studies on *S*. Kentucky ST198-X1-SGI1 CIP-R surveillance (Weill et al., [@B32]; Le Hello et al., [@B18], [@B17]), public health agencies in several different regions have notified the same isolation of *S*. Kentucky CIP-R in their animal flocks, in the environment, in food and in humans (traveler-related or domestic). We studied 70 *S*. Kentucky strains from the following participating countries: 41 strains collected from the French National Reference Center for *Salmonella* (FNRC-Salm), 11 from the French Food Safety Agency *Salmonella* network (ANSES Laboratory for Food Safety, Maisons-Alfort, France), six from Denmark (five from the Veterinary Clinical Microbiology Section, Department of Veterinary Disease Biology, University of Copenhagen and one from the Technical University of Denmark, DTU), five from Germany (three from the National Reference Laboratory for *Salmonella*, Federal Institute for Risk Assessment, BfR, and two from the German National Reference Center for Salmonellae and other Enterics, RKI), three from the NSW Enteric Reference Laboratory, ICPMR, Westmead Hospital, Sydney (Australia), two from the National Veterinary Research Institute (Poland) and one from the Institut Pasteur of Morocco, and the reference strain 98K (Edwards, [@B13]) from the WHO Collaborating Center for Reference and Research on *Salmonella*, Paris, France.

The global collection, presented in Table [1](#T1){ref-type="table"}, gathers *S*. Kentucky isolates from around the world (four continents, 28 countries) covering a long time-span (including preantibiotic era isolates, from 1937 to 2013), various livestock species (swine, turkey, layer, and broiler poultry farms), humans, food (soya bean, meat, seafood, and spices), wild and domestic animals (reptiles, horses, camels, birds, dogs) and the environment (compost and rivers).

###### 

**Characteristics of the *S. enterica* serotype Kentucky isolates that constitute the representative Kentucky ST198 collection in this study**.

  **Numbering**                                **Year of isolation**   **Country of contamination**   **Sources**             **AST[^a^](#TN1a){ref-type="table-fn"}**   ***bla* genes[^b^](#TN1b){ref-type="table-fn"}**   **Asp87 substitution in GyrA**         **CIP MIC mg/L**   **PFGE-type**   **MLST**   **SGI1[^c^](#TN1c){ref-type="table-fn"}**   **References[^d^](#TN1d){ref-type="table-fn"}**
  -------------------------------------------- ----------------------- ------------------------------ ----------------------- ------------------------------------------ -------------------------------------------------- -------------------------------------- ------------------ --------------- ---------- ------------------------------------------- -------------------------------------------------
  **HISTORICAL STRAINS (FROM 1937 TO 1999)**                                                                                                                                                                                                                                                                                                                 
  98K                                          1937                    USA                            Chicken                 Susceptible                                --                                                 No                                     0.008              X4              198        Absence                                     Edwards, [@B13]
  1--61                                        1961                    Senegal                        Human                   Susceptible                                --                                                 No                                     0.016              X1d             198        Absence                                     Le Hello et al., [@B18]
  1--66                                        1966                    Vietnam                        Human                   R2                                         TEM                                                No                                     0.016              X18             198        Absence                                     id
  1--68                                        1968                    Senegal                        Human                   SSu                                        --                                                 No                                     0.016              X1b             727        Absence                                     id
  2--75                                        1975                    Senegal                        Human                   Susceptible                                --                                                 No                                     0.023              X1b             198        Absence                                     id
  5--76                                        1976                    France                         Soya bean               Susceptible                                --                                                 No                                     0.008              X4              198        Absence                                     id
  19--85                                       1985                    Egypt                          meat                    SSpSuCTe                                   --                                                 No                                     0.016              X2b             198        J6                                          Le Hello et al., [@B18]
  93--6429                                     1993                    Indonesia                      Human                   Su                                         --                                                 No                                     0.016              X2c             198        J4                                          Le Hello et al., [@B19]
  96--11313                                    1996                    Egypt                          Human                   SSpGSuTe                                   --                                                 No                                     0.023              X1a             198        Ks                                          Le Hello et al., [@B18]
  97--6819                                     1997                    Egypt                          Human                   ASSpSuTe                                   TEM                                                No                                     0.008              X1a             198        Ks                                          id
  97--11473                                    1997                    Egypt                          Human                   R1-Nal                                     TEM                                                No[^1^](#TN1e){ref-type="table-fn"}    0.125              X1k             198        Ks                                          id
  99--2998                                     1999                    Egypt                          Human                   HR1-Nal                                    CMY-2                                              Asn                                    0.125              X1t             198        Absence                                     id
  **RECENT STRAINS (SINCE 2000)**                                                                                                                                                                                                                                                                                                                            
  **HUMAN**                                                                                                                                                                                                                                                                                                                                                  
  00--1059                                     2000                    Egypt                          Human                   R2-Nal                                     TEM                                                No[^1^](#TN1e){ref-type="table-fn"}    0.125              X1a             198        P1                                          id
  01--2100                                     2001                    Egypt                          Human                   R1-Nal                                     TEM                                                No[^1^](#TN1e){ref-type="table-fn"}    0.125              X1a             198        K1                                          id
  02--9866                                     2002                    Egypt                          Human                   R1-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   8                  X1a             198        Ks                                          id
  04--4567                                     2004                    Egypt                          Human                   R1-KTmpCNalCip                             TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   4                  X1g             198        K1                                          id
  05--1016                                     2005                    Kenya                          Human                   R3                                         --                                                 Tyr[^2^](#TN1f){ref-type="table-fn"}   4                  X1a             198        Q2                                          id
  05--4680                                     2005                    Sudan                          Human                   SSpGSuTmpNalCip                            --                                                 Gly[^2^](#TN1f){ref-type="table-fn"}   4                  X1l             198        K4                                          id
  07--1511                                     2007                    Morocco                        Human                   R2-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   16                 X1a             198        Ps                                          id
  07--7991                                     2007                    Tunisia                        Human                   R2-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   12                 X1b             198        \+                                          id
  08--4705                                     2008                    Iran                           Human                   R3                                         --                                                 Asn[^2^](#TN1f){ref-type="table-fn"}   12                 X1a             198        \+                                          id
  08--5707                                     2008                    Tanzania                       Human                   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   16                 X1c             198        \+                                          id
  09--8391                                     2009                    Morocco                        Human                   HR2-NalCip                                 CMY-2                                              Asn[^2^](#TN1f){ref-type="table-fn"}   32                 X1e             198        \+                                          Le Hello et al., [@B17]
  09--9322                                     2009                    Egypt                          Human                   HR3-NalCipAzi                              TEM-1 + CMY-2                                      Gly[^2^](#TN1f){ref-type="table-fn"}   12                 X1w             198        \+                                          id
  2010/00305                                   2010                    Egypt                          Human                   KCTmpNalCip                                --                                                 Gly[^2^](#TN1f){ref-type="table-fn"}   12                 X1w             198        \+                                          id
  2010/00720                                   2010                    Turkey                         Human                   HR4-NalCip                                 TEM-1 + CTX-M-1                                    Asn[^2^](#TN1f){ref-type="table-fn"}   16                 X1b             198        \+                                          id
  2010/01922                                   2010                    Morocco                        Human                   HR5-NalCip                                 TEM-1 + VIM-2                                      Gly[^2^](#TN1f){ref-type="table-fn"}   12                 X1m             198        \+                                          id
  2010/05456                                   2010                    Algeria                        Human                   HR6-NalCipAzi                              CTX-M-15                                           Asn[^2^](#TN1f){ref-type="table-fn"}   12                 X1a             198        Qs                                          id
  2010/07071                                   2010                    Cote d\'Ivoire                 Human                   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          This study
  2010/07297                                   2010                    Unknown                        Human                   ASul                                       PSE-1                                              No                                     0.016                              198        \+                                          This study
  2010/07503                                   2010                    India                          Human                   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1b             198        Ks                                          This study
  **RECENT STRAINS (SINCE 2000) HUMAN**                                                                                                                                                                                                                                                                                                                      
  2010/08553                                   2010                    Senegal                        Human                   R1-NalCip                                  TEM-1                                              Asn[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          This study
  2010/09778                                   2010                    Libya                          Human                   R1-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   24                                 1680       \+                                          This study
  2011/00664                                   2011                    Egypt                          Human                   R2-NalCipAzi                               OXA-48                                             Gly[^2^](#TN1f){ref-type="table-fn"}   8                  X1w             198        \+                                          Le Hello et al., [@B17]
  2011/01683                                   2011                    India                          Human                   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   \>32                               198        \+                                          This study
  2011/01801                                   2011                    Mali                           Human                   HR2                                        CMY-2                                              No                                     0.016              X3              1679       Absence                                     This study
  2011/06348                                   2011                    India                          Human                   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                                  198        \+                                          This study
  201111973                                    2011                    Cameroon                       Human                   R3                                         \-                                                 Gly[^2^](#TN1f){ref-type="table-fn"}   12                                 198        Qs                                          This study
  80-11-227-5139                               2011                    India                          Human                   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   6                                  198        \+                                          This study
  80-11-252-4482                               2011                    Iraq                           Human                   ASGSulCTeNalCip                            TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   8                                  198        \+                                          This study
  80-11-309-2385                               2011                    Cambodia                       Human                   ASulTeNalCip                               TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   8                                  198        \+                                          This study
  201203105                                    2012                    Indonesia                      Human                   R1-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   32                 X1a             198        Ks                                          This study
  201205363                                    2012                    Kuwait                         Human                   ASSpGTeNalCip                              TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   16                 X1l             198        Ks                                          This study
  201207374                                    2012                    Vietnam                        Human                   ASulTeNalCip                               TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   32                 X1c             198        Ks                                          This study
  2013/01062                                   2013                    Algeria                        Human                   HR7-NalCipAzi                              TEM-1 + OXA-48                                     Asn[^2^](#TN1f){ref-type="table-fn"}   8                  X1b             198        Ks                                          This study
  **NON HUMAN**                                                                                                                                                                                                                                                                                                                                              
  BfR 05-04625                                 2005                    Ethiopia                       Swine                   R3                                         --                                                 Gly[^2^](#TN1f){ref-type="table-fn"}   8                  X1a             198        \+                                          This study
  07AF4403                                     2006                    Ethiopia                       Chicken                 R1-NalCip                                  TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   12                 X1a             198        Ks                                          Le Hello et al., [@B18]
  Em 06-02339                                  2006                    United Arab Emirates           Camel                   R1-KNalCip                                 TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   8                                  198        \+                                          Münch et al., [@B24]
  Em 07-04654                                  2007                    United Arab Emirates           Houbara                 ASSpKTSulTeNalCip                          TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          id
  08-KS6                                       2008                    Nigeria                        Chicken                 R1-NalCip                                  TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   12                 X1a             198        Ks                                          Le Hello et al., [@B18]
  08-015                                       2008                    Morocco                        Seafood                 R1-TNalCip                                 Nd                                                 Asn[^2^](#TN1f){ref-type="table-fn"}   16                 X1d             198        Ks                                          id
  09-8745                                      2009                    Togo                           Chicken                 R1-NalCip                                  TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   12                                 198        Ks                                          This study
  K-50                                         2009                    Bangladesh                     Layer poultry farms     R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1e             198        \+                                          Barua et al., [@B4]
  K-26                                         2009                    Bangladesh                     Layer poultry farms     R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   16                 X1e             198        Ks                                          id
  BfR 10-02164                                 2010                    Germany                        Turkey meat             R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1b             198        Ks                                          Beutlich et al., [@B7]
  BfR 10-02979                                 2010                    Germany                        Reptile organs          R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   12                 X1n             198        Ks                                          id
  1090/10                                      2010                    Poland                         Turkey meat             R2-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   16                 X1b             198        \+                                          Zając et al., [@B34]
  10CEB962                                     2010                    France                         Compost                 R2-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          This study
  10CEB8465                                    2010                    Côte d\'Ivoire                 Poultry meat            R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                                  198        \+                                          This study
  10CEB8748                                    2010                    France                         Horse placenta          R1-TmpNalCip                               TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   16                                 198        \+                                          This study
  10CEB8766                                    2010                    France                         river                   SSpGSulTeNalCip                            --                                                 Asn[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          This study
  **NON HUMAN**                                                                                                                                                                                                                                                                                                                                              
  B-81                                         2010                    Bangladesh                     Broiler poultry farms   R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1a             198        \+                                          Barua et al., [@B5]
  B-11                                         2010                    Bangladesh                     Broiler poultry farms   R1-TTmpNalCip                              TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1e             198        \+                                          id
  K-78                                         2010                    Bangladesh                     Layer poultry farms     R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1i             198        \+                                          Barua et al., [@B4]
  2189/11                                      2011                    Poland                         Reptile                 R2-NalCip                                  TEM                                                Gly[^2^](#TN1f){ref-type="table-fn"}   16                 X1a             198        \+                                          Zając et al., [@B34]
  11CEB3342                                    2011                    France                         Spice                   R2-NalCip                                  TEM-1                                              Asn[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          This study
  11CEB4816                                    2011                    France                         Marinated turkey meat   R1-NalCip                                  TEM-1                                              Tyr[^2^](#TN1f){ref-type="table-fn"}   12                                 198        \+                                          This study
  12CEB716                                     2012                    France                         Dog                     R2-NalCip                                  TEM                                                Asn[^2^](#TN1f){ref-type="table-fn"}   8                                  198        \+                                          This study
  12CEB4452                                    2012                    France                         Turkey farms            R1-NalCip                                  TEM-1                                              Asn[^2^](#TN1f){ref-type="table-fn"}   16                 X1f             198        Ks                                          Guillon et al., [@B15]
  13CEB2160                                    2013                    Poland                         Turkey meat             R1-NalCip                                  TEM                                                Tyr[^2^](#TN1f){ref-type="table-fn"}   8                  X1x             198        Ks                                          This study

R1: resistance to amoxicillin, A; streptomycin, S; spectinomycin, Sp; gentamicin, G; sulfamethoxazole, Su; and tetracycline, Te.

R2: resistance to A.

R3: no resistance associated with NalCip.

ceftriaxone, Cro; ceftazidime, Caz; cefoxitin, Fox; trimethoprim, Tmp; chloramphenicol, C; azithromycin, Azi; imipenem, Imp; kanamycin, K; tobramycin, T; netilmicin, N; amikacin, A; isepamicin, I.

HR1: ACroCazFoxSSuTmpCTe.

HR2: ACroCazFox.

HR3: ACroCazFoxSSpKTNCSuTmp.

HR4: ACroSSpGSuTe.

HR5: ACroCazFoxImpSSpKTNGAISuTe.

HR6: ACroCazSSpKTGNAISulTmp.

HR7: AImpSSpGSuTmpTe.

Nd, not done; --, any bla gene found.

associated with the gyrA Ser83Phe substitution.

associated with the gyrA Ser83Phe substitution and parC Ser80Ile substitution.

+, positive for SGI1; Js, Ks, Ps, and Qs, variants of SGI1.

id, idem, same reference as above.

Microbiological investigations
------------------------------

Serotyping was performed on the basis of the White-Kauffmann-Le Minor scheme (Grimont and Weill, [@B14]). We carried out antimicrobial susceptibility testing (AST) on all *S.* Kentucky isolates with the disk diffusion method, for a panel of 32 antimicrobial drugs (Bio-Rad, Marnes-La-Coquette, France). Using Etests (bioMérieux, Marcy l\'′Etoile, France), we determined the minimum inhibitory concentration (MIC) of ciprofloxacin, as previously described (Le Hello et al., [@B17]). The results were then interpreted using the breakpoints of the Antibiogram Committee of the French Society for Microbiology (CA-SFM) which implements the EUCAST breakpoints. Resistance to ciprofloxacin is defined as having an MIC of more than 1 mg/L and being susceptible at an MIC of 0.5 mg/L or less, irrespective of isolate source (i.e., intestinal or extraintestinal).

For molecular typing, we performed multilocus sequence typing (MLST) on all *S.* Kentucky isolates and PulseNet standard pulsed-field gel electrophoresis (PFGE) of *Xba*I-digested chromosomal DNA on a selection of isolates (*n* = 50) (Le Hello et al., [@B18]; Achtman et al., [@B1]).

To determine the resistance mechanisms, we assessed the presence of β-lactam resistance genes (*bla*~*TEM*~, *bla*~*SHV*~, *bla*~*PSE*~, *bla*~*OXA*−1~ group, *bla*~*CMY*~, *bla*~*CTX*−*M*~, *bla*~*OXA*−48~, *bla*~*VIM*~, *bla*~*NDM*~, and *bla*~*KPC*~), plasmid-mediated quinolone resistance genes (known PMQR genes, *qnr*A, *qnr*B, *qnr*S, *qnr*D, *aac(6)′-Ib-cr*, *qep*A and the recent *oqx*A and *oqx*B), macrolide resistance genes (*mph*A) and *Salmonella* genomic island1 (SGI1) by PCR, as described previously (Le Hello et al., [@B17]; Li et al., [@B21]). Variants SGI1-K, P, and Q and J were differentiated in some strains (*n* = 28) by selected primers, as described in Table [2](#T2){ref-type="table"} and also described previously (Doublet et al., [@B12]; Le Hello et al., [@B19]).

###### 

**PCR set (SGI1- Ks, -Ps, and -Qs)**.

  **PCR No**.   **Primer**   **Nucleotide sequence (5\'-3\')**   **Tm(°C)**   **Size (bp)**             **Remark**
  ------------- ------------ ----------------------------------- ------------ ------------------------- -----------------------------------
  13            sulTER       AAGGATTTCCTGACCCTG                  59           2040                      \+ for SGI1-Ks
                RvTn501      ATGGATGTGGTGGCTGAAGG                67.2                                   
  A             FwS026       CGGTTTTGAATAAGAAGGCA                61.5         Variable                  \+ for SGI1-Ps
                OT4          CCAATGCTTAATCAGTGAGG                59.7                                   
  23            OT3          ATGAGTATTCAACATTTCCG                56.5         2192                      \+ for SGI1-Ps and -- for SGI1-Qs
                RvS044c      GTATTGTCGTCGGGATGATT                61.2                                   
  C             FwS026       CGGTTTTGAATAAGAAGGCA                61.5         Variable (\~1500--3000)   \+ for SGI1-Qs
                RvS044c      GTATTGTCGTCGGGATGATT                61.2                                   

The quinolone resistance-determining region (QRDR) of *gyr*A, *gyr*B, *par*C, and *par*E (encoding subunits of the DNA gyrase and the topoisomerase IV) was sequenced in all *S*. Kentucky strains as described previously (Le Hello et al., [@B17]). The nucleotide and deduced amino acid sequences were analyzed and compared with sequences available from the National Center for Biotechnology Information.

Results {#s3}
=======

The Table [1](#T1){ref-type="table"} presents the characteristics of serotype Kentucky isolates and summarizes the results of antimicrobial resistance and genomic typing.

Molecular typing
----------------

All but one of the 70 *S*. Kentucky isolates belonged to the e-burst group 56: ST198 and two single locus variants (SLV), ST727 and ST1680. The remaining isolate belonged to a new ST, ST1679, sharing only three loci out of seven (this isolate was susceptible to quinolones and belonged to an X3 PFGE type). We distinguished diverse PFGE types among the ST198 and SLV isolates. The major one, X1 and its many variants (X1a--X1x), representing almost 90% of the ST198 isolates (*n* = 44), has been associated with strains isolated over the last 50 years, whereas X2 (*n* = 2/*N* = 50) has been linked to isolates from Asia isolated before the 2000s and several other patterns for older strains isolated before the 1980s (X4 for the reference strain 98K and strain 5--76 isolated from soya bean, and X18 for a Vietnamese strain, isolated in 1937, 1976, and 1966, respectively). Most common representative PFGE subtypes are shown in Figure [1](#F1){ref-type="fig"}.

![**Representatives of *Xba*I-PFGE profiles obtained among *S. enterica* serotype Kentucky isolates from humans and nonhumans during the period 1937--2013**.](fmicb-04-00395-g0001){#F1}

The SGI1-K variants were firstly identified in Kentucky ST198 isolates from Egypt in 1996. Then, the SGI1-Ks and its derivative variants -Ps or -Qs were present in all the ST198 (or its SLV) isolates. As shown here, all the SGI1 variants were independently distributed between periods, countries and sources (Table [1](#T1){ref-type="table"}).

Antimicrobial susceptibility testing and resistance genes
---------------------------------------------------------

Among the *S.* Kentucky isolates studied, increased resistance to fluoroquinolones has been observed since the isolation of the first ciprofloxacin-resistant isolate in 2002. As shown in Table [1](#T1){ref-type="table"} ciprofloxacin MICs seem to increase over time, from 0.008 mg/L to 0.125 mg/L during the 1990s, 4 mg/L to 12 mg/L between 2002 and 2006 and since 2007 with the emergence of highly ciprofloxacin resistant strains (16 to \>32 mg/L). Apart from quinolone resistance, additional resistance was observed in some *S.* Kentucky CIP-R isolates (Table [1](#T1){ref-type="table"}). The most prevalent drug resistance patterns were R1 (*n* = 25, 46%), which included resistance to amoxicillin, streptomycin, spectinomycin, gentamicin, sulfamethoxazole, and tetracycline; R2 (*n* = 8, 15%), which included resistance to amoxicillin; and R3 (*n* = 4, 7%), which included resistance only to nalidixic acid and ciprofloxacin. Before 2002, these resistance patterns were also described with decreased susceptibility to ciprofloxacin (CIP-DS; MIC, 0.125 mg/L). These patterns and other less frequent ones were all associated with the presence of SGI1-Ks (for R1) and -Ps (for R2), both carrying the *bla*~*TEM*~ gene, and -Qs (for R3 which do not carry any drug resistance genes).

More recently, additional resistance to third generation cephalosporins (C3G) and/or carbapenems was observed in CIP-R *S.* Kentucky X1-ST198-SGI1 isolates. These isolates contained the cephamycinase *bla*~*CMY*−2~ (*n* = 3), the ESBLs *bla*~*CTX*−*M*−1~ (*n* = 1) and *bla*~*CTX*−*M*−15~ (*n* = 1), and the carbapenemases *bla*~*VIM*−2~ (*n* = 1) and *bla*~*OXA*−48~ (*n* = 2). High-level resistance to azithromycin (32 mg/L to 128 mg/L) was found in four of them which carried the phosphotransferase *mph*A gene known to inactivate macrolide antimicrobial drugs.

In addition to the ST198-X1 SGI1-Ks, -Ps, and -Qs isolates, we observed other drug-resistant *S.* Kentucky ST198 populations in our collection. Initially, we identified ST198-X2, which carried SGI-Js and was isolated in Asia before the 2000s (see Le Hello et al., [@B19]); secondly, we identified here for the first time a putative SGI1-B variant carrying *S.* Kentucky ST198 isolate (no. 2010/07297) which contains a *bla*~*PSE*−1~ gene found occasionally in other serotypes such as Typhimurium DT104 and Paratyphi B d-tartrate fermenting (Boyd et al., [@B9]; Weill et al., [@B33]). Lastly, an SGI1 free isolate susceptible to nalidixic acid and producing the CMY-2 cephamycinase was acquired in Mali in 2011 (no. 2011/01801).

Temporal and geographic distribution of *s*. kentucky isolates with QRDR mutations
----------------------------------------------------------------------------------

As shown in Table [1](#T1){ref-type="table"}, ciprofloxacin resistance in all the 54 CIP-R *S*. Kentucky isolates was related to GyrA and ParC substitutions (Table [1](#T1){ref-type="table"}). All contained double substitutions in GyrA (at codons Ser83 and Asp87) and a single ParC substitution (Ser80 encoding an isoleucine residue). None of the isolates contained GyrB or ParE modifications. In GyrA, all the isolates contained phenylalanine at codon Ser83, whereas mutations in codon Asp87 resulted in different substitutions to asparagine (Asn), tyrosine (Tyr), or glycine (Gly) residues depending on the geographic origin of the isolates (Figure [2](#F2){ref-type="fig"}). All the Egyptian isolates presented three possible mutations in codon Asp87 (*n* = 6), whereas the isolates from North Africa (Morocco, Algeria, Tunisia, Libya) had a modification that resulted in Asp87Asn (*n* = 7). An exception was the VIM-2 producing Kentucky 2010/01922 isolate from Morocco which had Asp87Tyr. Those from the Middle East (Iraq, United Arab Emirates, Kuwait, Turkey, and Iran) presented both Asp87Gly and Asp87Asn, apart from two nonhuman Ethiopian isolates and one Sudanese human isolate in 2005 that had an Asp87Gly substitution; those from East Africa, India and Bangladesh had an Asp87Tyr modification (*n* = 12). Apart from the two strains from the Ivory Coast which presented Asp87Tyr, those from West Africa presented Asp87Gly (*n* = 3). All three isolates from Southeast Asia (Cambodia, Indonesia and Vietnam) had an Asp87Asn amino acid change.

![**Geographical distribution in the eastern hemisphere of the different substitutions at codon 87 of GyrA to asparagine (Asn), tyrosine (Tyr), or glycine (Gly) in *S. enterica* serotype Kentucky resistant to ciprofloxacin of the present collection**. H, Human isolates; V, nonhuman isolates.](fmicb-04-00395-g0002){#F2}

Isolates from food, animal feed and the environment isolated in Europe presented an intermediate situation with isolates mostly having an Asp87Tyr residue in Germany and Poland and an Asp87Asn residue in France.

No PMQR genes, such as *qnr, aac(6′)-Ib-cr, qepA* and *oqxAB* were detected in *S*. Kentucky CIP-R isolates of this study.

Nonhuman sources of the *s*. kentucky ST198-x1-SGI1 strain
----------------------------------------------------------

The nonhuman isolates of *S*. Kentucky ST198-X1-SGI1 have mainly been found in poultry farms (chicken, layer and turkey, *n* = 14) since its first description in a chicken from Ethiopia in 2006 (Le Hello et al., [@B18]). This strain has further been described in poultry flocks in East, West and North Africa, the Indian sub-continent and Europe. It has also been described in food products (seafood, meat, or spice), domestic animals (dog, horse, camel, or pet reptiles) and wild animals (houbara or reptiles) and various environments (river or compost) (see Table [1](#T1){ref-type="table"}).

Discussion {#s4}
==========

By gathering and studying this global collection, we confirmed that one strain has disseminated throughout the developing countries in both human and nonhuman sources. Strain ST198-X1 displays high-level resistance to ciprofloxacin and harbors SGI1-Ks or its derivative variants -Ps or -Qs. The high-diversity of antibiotic resistance patterns could be related to genetic rearrangements mediated by various insertion sequences (in particular IS26) and transposons in SGI1-Ks, -Ps, and -Qs (Doublet et al., [@B12]). In parallel, contrary to the relatively few PFGE patterns associated with *S*. Typhimurium DT104, *S*. Kentucky ST198 displayed high-diversity in X1 subtypes, suggesting frequent events of genomic rearrangements present in SGI1 or the acquisition/loss of various plasmids. Several other ST198 strains belonging to other PFGE subtypes and/or containing different antibiotic resistance mechanisms have been isolated sporadically or have no longer been isolated since the 2000s (Le Hello et al., [@B19]). The odyssey of the *S*. Kentucky ST198-X1 isolate has lasted since it was found in Egypt in the mid-1990s. It has since then accumulated various chromosomal resistance determinants, with the integration of SGI1 (encoding resistance to multiple antimicrobial drugs), followed by cumulative mutations in the *gyr*A and *par*C genes, leading to resistance to nalidixic acid, and then to ciprofloxacin in 2002. Since 2002, this strain has spread rapidly throughout Africa and the Middle East (Le Hello et al., [@B18]) and, in 2009, it was identified in India in travelers and in Bangladesh in poultry flocks (Barua et al., [@B4], [@B5]). Furthermore, the first description of SGI1 variant K was identified in a *Salmonella* serotype Kentucky strain isolated in 2001 from spices imported into Australia from India (Levings et al., [@B20]). Since 2011, a pattern of propagation across Asia is also suggested by the recent recovery of ciprofloxacin-resistant *S*. Kentucky isolates from stool samples of patients in France and Australia with a history of recent travel to Vietnam, Cambodia and Indonesia. This global collection also makes it possible to confirm the recent increase of *S*. Kentucky ST198-X1-SGI1 CIP-R clinical strains that have acquired additional genes, making them resistant to extended spectrum cephalosporins and/or carbapenems, in particular in the Mediterranean basin (Collard et al., [@B11]; Le Hello et al., [@B17]). High-level resistance to azithromycin due to the acquisition of the *mph*A gene among these isolates is of concern as this antimicrobial agent is presented as a good alternative treatment for severe *Salmonella* infections (Hill and Beeching, [@B16]) and it completes the variety of enteric bacteria already described producing this phosphotransferase (Boumghar-Bourtchai et al., [@B8]). Last but not least, as shown in this study, ciprofloxacin MIC has increased decade after decade in *S*. Kentucky isolates. The recent increase in MIC is not due to additional mutations in QRDR, nor to the presence of PMQR. However, the increase could be due to the overexpression of an efflux system such as AcrAB-TolC (Baucheron et al., [@B6]).

Another matter of concern is the expanding livestock reservoir of this *S*. Kentucky ST198-X1-SGI1 CIP-R strain, initially identified in African autochthonous poultry but subsequently found in various animals and food (Le Hello et al., [@B18]; Barua et al., [@B4], [@B5]; Beutlich et al., [@B7]; Münch et al., [@B24]; Wasyl and Hoszowski, [@B30]). Poultry flocks have contributed to the global dissemination of this clone in developing countries since 2005. Hence this strain was isolated in Ethiopia in 2006 (chicken), Nigeria (chicken), and Morocco (turkey) in 2008 (Le Hello et al., [@B18]), in Togo (chicken) in 2009, and from layers in 2009, from broilers in 2010 in Bangladesh (Barua et al., [@B4], [@B5]), and in developed countries since 2010 (Poland, Wasyl and Hoszowski, [@B30]; Germany, Beutlich et al., [@B7]; and France, Guillon et al., [@B15]). Interestingly, the *S*. Kentucky ST198-X1-SGI1 CIP-R identified in Europe was exclusively associated with turkeys. An investigation following the epidemics in Poland (Wasyl and Hoszowski, [@B30]) has established that at least one of the infected flocks was hatched from eggs imported from the Middle East. The diversity of nonhuman sources described in this study is another reason of concern. In particular, the description of *S*. Kentucky ST198-X1-SGI1 CIP-R in the environment (rivers and compost) and animals such as reptiles, indicates its potential long-term presence, suggesting its capacity to produce biofilm, as was previously identified in Tunisian isolates (Turki et al., [@B28]). This intrinsic characteristic could possibly facilitate secondary contaminations and persistence into a novel host/source but this remains to be investigated.

Regarding its recent establishment in Bangladesh (18% of 500 farms were *S*. Kentucky positive during the period 2009--2010), we do not have any information on how *S*. Kentucky ST198-X1-SGI1 CIP-R was introduced in poultry, although locally produced fish meal used as a protein source has been associated with the presence of *Salmonella* in flocks (Barua et al., [@B4], [@B5]). Small poultry farmers purchase this raw ingredient from the local market to produce low-cost feed by mixing it with other ingredients. Meat and bone meal imported from different countries are also used for preparing poultry and fish feed as a source of protein. Regarding broiler chicks, they are supplied from commercial breeding farms. Further investigations are necessary to obtain information on locally produced poultry feed. The microbiological characteristics of Kentucky ST198-X1-SGI1 CIP-R isolated from poultry farms in Bangladesh indicated that the amino acid substitution in codon 87 of GyrA was exclusively a tyrosine residue like that found in Kentucky for India, East Africa, Egypt and in some Middle East countries. We do not know whether humans play any role in the introduction of this strain in various flocks. Regarding this, it is noteworthy that several million emigrants from Bangladesh work in the Middle East. The human role in the contamination of livestock by *S*. Kentucky ST198-X1-SGI1CIP-R has been pinpointed recently in local turkey flocks in France. The epidemiological investigation performed highlighted the introduction of this strain following the return of farmers from Morocco, a country where this strain is endemic, and suffering from diarrhea (Guillon et al., [@B15]). This hypothesis may be further reinforced as this isolate (12CEB4452) presented GyrA Asp87Asn substitution which is clearly associated with the North African *S*. Kentucky ST198-X1-SGI1 CIP-R, while isolate 13CEB2160, found in turkey meat sold in France but imported from Poland, presented tyrosine substitution, a characteristic described more frequently in Polish turkey flocks.

In the era of globalized food supply, livestock, and international human travel, the ciprofloxacin-resistant *S.* Kentucky ST198-X1-SGI1 strain is not restricted to one country, rendering measures to subject livestock to controls more difficult. National and international health, food, and agricultural authorities should include it among the strains targeted in national programs to control *Salmonella* spp in poultry. Based on different studies, including this one, the *S.* Kentucky ST198-X1-SGI1 epidemic clone of interest can nowadays easily be identified by simple serotyping (Kentucky) and by testing its susceptibility *in vitro* to ciprofloxacin (disk diffusion or MIC). It is essential to consider this strain at both national and international level, in order to take preventive measures as soon as possible to limit its worldwide propagation. Like this, we suggest including this emerging *Salmonella* in the European Union\'s list of target serotypes for mandatory monitoring (EU Commission regulations No.200/2012 of 8 March 2012).
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